Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Alei Feng"'
Autor:
Jianan Li, Wentao Zhang, Yi Zhao, Jixian Li, Yuanliu Nie, Alei Feng, Qiang Li, Fengge Zhou, Renya Zeng, Zhe Yang
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background With a series of clinical trials confirming the sensitivity of small cell lung cancer (SCLC) to immunotherapy, research on personalized treatment for SCLC has gained increasing attention. Currently, the most widely accepted subtyp
Externí odkaz:
https://doaj.org/article/b0505ec0cd5047b9aaa0129f142b0be4
Autor:
Alei Feng, Yanjun Li, Guangxu Li, Yu Wang, Qiang Wen, Zhe Yang, Kaihua Tian, Hongying Lv, Lijie Guo, Shanshan Zhang, Xiaoyan Liu, Da Jiang
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundThe genomic features of cancer cells may confer the metastatic ability of lung adenocarcinoma (LUAD) to metastasize to specific organs. We aimed to identify the differences in genomic alterations between patients with primary LUAD with and
Externí odkaz:
https://doaj.org/article/d00f31ac14554a0494188d46ba97fad1
Autor:
Xiaolin Sun, Ning Yang, Xingguo Zhou, Honghai Dai, Qiang Li, Alei Feng, Gongwen Xu, Yingchao Liu, Linzong Xu, Zhanyu Zhang, Zhe Yang, Xiaomei Li
Publikováno v:
Frontiers in Genetics, Vol 13 (2022)
Breast cancer (BC) is the second leading cause of brain metastases (BM), with high morbidity and mortality. The aim of our study was to explore the effect of the cartilage intermediate layer protein (CILP) on breast cancer brain metastases (BCBM). Us
Externí odkaz:
https://doaj.org/article/54b9234b8afb4a29b1ba7b557cc46898
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundThe combination of immunotherapy and chemoradiotherapy has become the standard therapeutic strategy for patients with unresected locally advance-stage non-small cell lung cancer (NSCLC) and induced treatment-related adverse effects, particu
Externí odkaz:
https://doaj.org/article/39231738fd2d428b998486614a1ef28c
Publikováno v:
Cancer Medicine, Vol 9, Iss 5, Pp 1628-1637 (2020)
Abstract Background Definitive chemoradiation therapy (dCRT) is the standard treatment for patients with nonsurgical esophageal squamous cell carcinoma (ESCC), yet patients have demonstrated great variations in their responses to dCRT and inevitably
Externí odkaz:
https://doaj.org/article/82f575617bb74847a7df75ef503fce94
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Estimated glomerular filtration rate (EGFR)-sensitive mutations are extremely important for targeted treatment strategies in lung cancer. Osimertinib can effectively inhibit the activity of EGFR-sensitive mutations, including the T790M mutation. Howe
Externí odkaz:
https://doaj.org/article/0ad622c7a19d4f39a4592f2b3febac32
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundThe present study compared the predictive performance of pretreatment computed tomography (CT)-based radiomics signatures and clinicopathological and CT morphological factors for ligand programmed death-ligand 1 (PD-L1) expression level and
Externí odkaz:
https://doaj.org/article/c4d4fdbef4c145aea19daf578202b221
Autor:
Jisheng Li, Lei Cong, Jintao Liu, Ling Peng, Jun Wang, Alei Feng, Jinbo Yue, Li Li, Xiuwen Wang, Xiangling Wang
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
BackgroundMicrosatellite stable (MSS) or mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) is resistant to immune checkpoint inhibitors. However, a recent Japanese trial showed that regorafenib plus nivolumab had encouraging anti-
Externí odkaz:
https://doaj.org/article/a72b686a6d984aeda8c5984f32b48e06
Autor:
Alei Feng, Ning Yang, Ruoying Yu, Jingwen Liu, Jiaohui Pang, Xue Wu, Yang Shao, Zhe Yang, Honghai Dai
Publikováno v:
OncoTargets and therapy
Alei Feng,1,2 Ning Yang,1 Ruoying Yu,3 Jingwen Liu,3 Jiaohui Pang,3 Xue Wu,3 Yang Shao,3,4 Zhe Yang,1 Honghai Dai1 1Tumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 2500
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::701eec73efb1ac273925415b58678e3a
https://doi.org/10.2147/ott.s334580
https://doi.org/10.2147/ott.s334580
Autor:
Yuanliu Nie, Guangyue Yao, Liang Li, Alei Feng, Wentao Zhang, Xiaoying Xu, Qiang Li, Zhe Yang
Publikováno v:
Cancer management and research. 14
Yuanliu Nie,1 Guangyue Yao,1 Liang Li,2 Alei Feng,3 Wentao Zhang,4 Xiaoying Xu,5 Qiang Li,1,3 Zhe Yang1,3 1Tumor Research and Therapy Center, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, Peopleâs Republic of China;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1171e767e43a8a25c17cc16b8045523a
https://pubmed.ncbi.nlm.nih.gov/35967755
https://pubmed.ncbi.nlm.nih.gov/35967755